Douglas Cunningham, DO
Family Medicine · Phoenix, AZNPI 1104856475
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,277,520 of the $1,813,682 with a category attached, or 70.4%. 36 manufacturers reported payments, led by Viiv Healthcare Company at 44.8% of the total. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,043 payments — averaging $596.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$812K
- Gilead$448K
- Janssen Products, LP$329K
- Merck$111K
- EMD Serono, Inc.$66K
- Janssen Scientific Affairs, LLC$15K
- plus $32K from 30 others
Across 445 payments — averaging $6957.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.3M
- Viiv Healthcare Company$528K
- Gilead$145K
- GSK$53K
- Janssen Research & Development, LLC$49K
- Pfizer$8K
What the payments were for
- Consulting fees$178,49810%
- Speaking & faculty fees$1,277,52070%
- Travel & lodging$300,12217%
- Food & beverage$57,1813%
- Education$1850%
- Gifts$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 1,099 | $811,981 |
| Gilead | 838 | $448,364 |
| Janssen Products, LP | 365 | $329,103 |
| Merck | 252 | $111,296 |
| EMD Serono, Inc. | 114 | $66,171 |
| Janssen Scientific Affairs, LLC | 38 | $15,128 |
| Theratechnologies Inc. | 44 | $12,106 |
| Napo Pharmaceuticals Inc | 27 | $8,282 |
| Lilly USA, LLC | 16 | $6,002 |
| Johnson & Johnson(2 entities) | 122 | $2,089 |
| GSK | 7 | $892 |
| AbbVie | 45 | $804 |
| Abbott | 11 | $233 |
| Novo Nordisk | 11 | $214 |
| AstraZeneca | 12 | $171 |
| Boehringer Ingelheim | 6 | $126 |
| Lucid Diagnostics Inc. | 3 | $116 |
| Teva Pharmaceuticals USA, Inc. | 6 | $103 |
| Astellas Pharma US Inc | 3 | $94 |
| Amgen | 4 | $76 |
| Medtronic | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Intra-sana Laboratories | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,813,682 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 530 | $2,109,410 |
| DovatoDolutegravir Sodium/Lamivudine | 174 | $519,506 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 98 | $456,779 |
| SerostimSomatropin | 19 | $382,404 |
| CabenuvaCabotegravir/Rilpivirine | 49 | $296,439 |
| DescovyEmtricitabine/Tenofov Alafenam | 131 | $291,257 |
| TivicayDolutegravir Sodium | 112 | $251,829 |
| IsentressRaltegravir Potassium | 113 | $218,622 |
| PifeltroDoravirine | 99 | $180,561 |
| PrezcobixDarunavir/Cobicistat | 76 | $179,596 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 41 | $175,851 |
| RukobiaFostemsavir Tromethamine | 13 | $113,859 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 25 | $94,269 |
| JulucaDolutegravir/Rilpivirine | 20 | $74,721 |
| Maraviroc | 47 | $72,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Vemlidy | $448,364 | $2,419,638675 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay, Triumeq, Rukobia | $811,981 | $1,432,206409 claims |
| MerckIsentress, Pifeltro, Delstrigo, Isentress Hd, Januvia | $111,296 | $561,072318 claims |
| Janssen Products, LPSymtuza | $329,103 | $456,77998 claims |
| EMD Serono, Inc.Serostim | $66,171 | $382,40419 claims |
| Johnson & JohnsonPrezcobix, Complera | $2,089 | $222,04388 claims |
| Boehringer IngelheimJardiance, Tradjenta | $126 | $69,904100 claims |
| AmgenOtezla | $76 | $51,71912 claims |
| Novo NordiskOzempic | $214 | $29,96027 claims |
| AstraZenecaFarxiga, Symbicort | $171 | $22,82638 claims |
| Janssen Scientific Affairs, LLCIntelence | $15,128 | $20,24014 claims |
| AbbVieCreon | $804 | $12,90418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
- James BeachPhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.